## **Core Concept**
The question revolves around the management of Non-Small Cell Lung Cancer (NSCLC) with a specific mutation, EGFR T790M. This mutation is a known mechanism of resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs). The EGFR T790M mutation involves a substitution at position 790 in the EGFR gene, leading to resistance to drugs like gefitinib and erlotinib.

## **Why the Correct Answer is Right**
The correct answer, **Osimertinib**, is a third-generation EGFR TKI that is specifically designed to target the EGFR T790M mutation. It has shown significant efficacy in patients with NSCLC who have developed resistance to first-generation EGFR TKIs due to the T790M mutation. Osimertinib works by selectively inhibiting the mutated EGFR, thereby reducing tumor growth. Its ability to cross the blood-brain barrier also makes it effective against central nervous system metastases.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Gefitinib is a first-generation EGFR TKI. It is effective in NSCLC patients with EGFR mutations but not specifically against the T790M mutation, which confers resistance to first-generation TKIs.
- **Option B:** Erlotinib is another first-generation EGFR TKI, similar to gefitinib. It has limited activity against the T790M mutation.
- **Option D:** Crizotinib is a MET and ALK inhibitor, not specifically targeting the EGFR T790M mutation. It is used in a different subset of NSCLC patients, particularly those with ALK or MET alterations.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the EGFR T790M mutation is a common mechanism of resistance to first-generation EGFR TKIs in NSCLC. Osimertinib is specifically approved for patients with EGFR T790M mutation-positive NSCLC who have progressed on or during treatment with another EGFR TKI. This highlights the importance of molecular profiling in guiding treatment decisions in NSCLC.

## **Correct Answer:** . Osimertinib